Pacific Edge Limited (PFGTF) has released an update.
New Zealand-based Pacific Edge, a leading cancer diagnostics firm, is still awaiting the finalization of the Medicare coverage determination for its suite of Cxbladder tests, as discussions between Novitas and CMS continue with no specified timeline. Meanwhile, their tests remain covered by Medicare at historical rates, adhering to medical necessity guidelines. The company has assured shareholders that further updates will be communicated once more information is available.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
